SIRT6、HIF-1α与甲状腺乳头状癌发生发展的关系

The Relationship between SIRT6,HIF-1αand the Occurrence and Development of Papillary Thyroid Carcinoma

甲状腺乳头状癌(PTC)是分化良好的甲状腺癌的主要类型,PTC的长期预后非常好,在10年的随访中,成人的生存率为92%~98%。但是,有5%~20%的患者发生局部或区域性复发,需要进一步治疗,而10%~15%的患者继续发生远处转移。影响预后的因素很多,其中包括性别,就诊年龄,组织学和肿瘤分期。在过去的三十年,甲状腺癌的发病率增加了两倍,归因于乳头状亚型的迅速崛起。PTC的大规模基因组特征揭示了遗传改变在该疾病的肿瘤发生中的关键作用。但是,PTC的致癌作用是一个复杂的生物学过程,其特征是各种分子异常,因此对其高发的原因仍知之甚少。因此,对于诊断和预后,仍然迫切需要研究PTC的发病机制和进展,解码新颖的分子靶标或进程[1]。

Papillary thyroid carcinoma(PTC)is the main type of well-differentiated thyroid cancer.The long-term prognosis of PTC is very good.During the 10-year follow-up,the adult survival rate is 92%~98%.However,5%~20%of patients have local or regional recurrence and require further treatment,while 10%~15%of patients continue to develop distant metastases.There are many factors that affect the prognosis,including gender,age at diagnosis,histology and tumor stage.The incidence of thyroid cancer has tripled in the past three decades,due to the rapid rise of papillary subtypes.The large-scale genomic characteristics of PTC reveal the key role of genetic changes in the tumorigenesis of this disease.However,the carcinogenic effect of PTC is a complex biological process,which is characterized by various molecular abnormalities,so the reasons for its high incidence are still poorly understood.Therefore,for diagnosis and prognosis,there is still an urgent need to study the pathogenesis and progress of PTC,and to decode novel molecular targets or processes[1].